Improving Vascular Access for Dialysis with Humacyte

Share this page

In July 2018, Fresenius Medical Care announced a global partnership with Humacyte, to make their human acellular vessel, HUMACYL®, available to more hemodialysis patients worldwide upon approval by appropriate regulatory authorities. In this video, Dr. Frank Maddux takes us into their lab to explain how this bioengineered blood vessel will potentially improve vascular access and health outcomes for our patients in need of dialysis. For more information about this partnership, please also read our Q&A with Carrie Cox, Humacyte’s Executive Chairman and former Chief Executive Officer.